Financial News · Live Terminal

Page 115 of 316

Jefferies Upgrades Olympus to Buy from Hold; Adjusts Price Target to 2,300 Yen from 1,700 Yen

BMO Downgrades Hanover Insurance to Market Perform From Outperform, Adjusts PT to $203 From $194

Hanover Insurance Group (THG) has an average rating of overweight and mean price target of $203.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$THG

Research42d ago

Loop Capital Initiates Corpay at Buy With $406 Price Target

Corpay (CPAY) has an average rating of overweight and mean price target of $389.93, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CPAY

Research42d ago

HSBC Upgrades Credicorp to Buy From Hold, Adjusts Price Target to $350 From $320

Credicorp (BAP) has an average rating of overweight and mean price target of $359.66, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BAP

Research42d ago

Bernstein Upgrades American Tower to Outperform From Market Perform, Price Target is $207

American Tower (AMT) has an average rating of overweight and mean price target of $216.14, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AMT

Research42d ago

Citic Securities Upgrades Philip Morris International to Buy From Add

Philip Morris International (PM) has an average rating of overweight and mean price target of $192.42, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$PM

Research42d ago

UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $307 From $188

Jazz Pharmaceuticals (JAZZ) has an average rating of overweight and mean price target of $245.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$JAZZ

Research43d ago

Research Alert: CFRA Maintains Hold Opinion On Shares Of Baidu

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target at USD150, on a P/E of 16.5x our 2027 EPADS view, near peers. We lower our 2026 EPADS estimate to CNY50.87 from CNY55.39 and 2027's to CNY60.72 from CNY62.50. BIDU's full-stack AI capabilities, spanning from Kunlunxin chips and cloud infrastructure to ERNIE foundation models and end-user applications, provide a significant competitive advantage through end-to-end optimization and superior cost and performance. We think that BIDU will see strong demand for AI inference workloads led by AI agents and applications, which plays directly to its strengths in GPU cloud and its MaaS platform. We also see margins benefiting as GPU cloud is structurally more profitable than traditional CPU cloud. We view BIDU's international expansion efforts, including Apollo Go's entry into European and Middle Eastern markets and the launch of an overseas digital human platform targeting global e-commerce, as important growth catalysts. Still, elevated spending needs and fair valuation keep us neutral.

$BIDU

Research43d ago

Research Alert: CFRA Lowers Rating To Hold From Buy On Shares Of Citigroup, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price $17 to $133, using a narrower equity risk premium and a forward 2026 P/E of 12.3x vs. the three-year historical average of 11.3x. We reduce our 2026 EPS by $0.45 to $10.85 and 2027's by $0.30 to $12.20 on revenue projections of $93.4B and $96.4B, respectively. C's shares have outperformed the peer group (+5% YTD and +62% in the last 12 months). Following strong Q1 2026 results, we think it will be challenging to reach outsize performance in Markets (trading services), which more than offsets weakness in Banking. We believe macroeconomic trends may face uncertainties from the U.S.-Iran conflict that could trigger tail risks including inflationary pressures and lower consumer confidence. Should we see a U.S. economic slowdown, we believe loan transaction volumes may ease, affecting credit card income and commercial loan activity. Given that the bank's multiyear restructuring is complete, macroeconomic trends will determine top-line growth and profitability, both of which face risks.

Research43d ago

Barrington Downgrades ZSpace to Market Perform From Outperform

$ZSPC

Research43d ago

Research Alert: CFRA Keeps Hold Opinion On Lp Units Of Plains All America

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target of $25 (up $4) reflects a combination of our relative valuation and DCF model analyses. On a relative basis, we apply an 11.0x multiple of enterprise value to 2027 EBITDA, in line with peers. That approach yields a value of $22 per unit. Our DCF model uses medium-term FCF growth of 4.0% per year, 2.0% terminal growth, discounted at a WACC of 7.7%, and yields a value of $28 per unit. We lift our 2026 earnings per unit estimate by $0.24 to $1.85 and 2027's by $0.23 to $1.98. PAA has technically closed on the sale of its Canadian NGL assets to Keyera Corp. for approximately CAD5.3 billion in cash despite a challenge by the Canadian Competition Bureau. Should the Bureau prevail in court, we think it could demand a post-sale remedy, which might include forcing Keyera to either unwind this recent transaction, or forcing a sale of some or all of the NGL assets to a third party. We continue to see crude oil logistics as PAA's core strategic business.

$PAA

Research43d ago

Research Alert: CFRA Lowers Shares Of Bank Of America Corporation To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price by $5 to $55, applying a narrower equity risk premium and a forward P/E of 12.1x compared to the three-year historical average at 12.3x. We keep our EPS estimates at $4.55 in 2026 and $5.00 in 2027, near consensus estimates on revenue projections of $1203B and $125B, respectively. We think core areas of business may witness a slowdown in 2026 due to the Iran-U.S. war's impact on inflation and cost of living. There are also tail risks that could negatively impact BAC's growth, such as consumer spending and loan balances, commercial loans, and commercial real estate refinancings. After further review of Q1 2026 results, we see that outsize performance from Global Markets (trading services) offset modest Q/Q gains in Consumer Banking and Global Banking. We believe the Fed may dig in their heels with a rate-neutral regime and a higher rate bias until there is greater clarity from the outcome of the Iran-U.S. war. BAC shares are down 9.5% year-to-date and trade with a 2.25% dividend yield.

$BAC

Research43d ago

Research Alert: Nextera-dominion Merger: Initial Reaction Tilts Toward A Negative View

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:NextEra Energy announced a proposed all-stock merger with Dominion Energy, creating the world's largest regulated electric utility with $249B market cap and $420B enterprise value. Dominion shareholders would receive 0.8138 NEE shares per D share, with NEE shareholders owning 74.5% of the combined entity. Our initial reaction tilts negative on the merger, as financial benefits appear modest relative to transaction complexity and regulatory risks. Management expects the deal to be immediately EPS accretive with 9%+ long-term adjusted EPS CAGR versus 8%+ standalone, plus improved rate base growth and regulatory mix. However, we see material approval risks given expected resistance from Virginia and South Carolina regulators, with NEE facing $4.83B-$6.52B termination fees if the deal fails. We question whether NEE could achieve that incremental 1% EPS growth organically rather than through this complex merger, and whether the PJM expansion remains attractive given increasing uncertainties.

$NEE

Research43d ago

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares of Regeneron are down more than 10% today after the company announced on Friday evening, after market close, that the Phase 3 study of fianlimab did not achieve a statistically significant primary endpoint in progression-free survival (PFS). The advanced clinical trials were assessing fianlimab in combination with cemiplimab (PD-1 inhibitor) for first-line unresectable or metastatic melanoma, a skin cancer that has spread beyond its original location versus pembrolizumab (PD-1 inhibitor), which is Merck's blockbuster oncology drug, Keytruda. While the company aims to present detailed data at an upcoming medical meeting, the release reflects diminished prospects for what had been anticipated as a highly promising treatment with a blockbuster potential, in our view. We lower our target price to $650 from $846, based on 12.4x our 2027 EPS estimate, a discount to REGN's 10-year historical forward P/E average. We retain our 2026 EPS estimate at $45.59 and our 2027 EPS estimate at $52.62.

$REGN

Research43d ago

Research Alert: Bio-rad Laboratories Rallies On Wsj Report Of Elliott Management Stake

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares rallied on a WSJ report that activist firm Elliott Management owns a meaningful stake in BIO, though the specific ownership level remains undisclosed. Elliott has made multiple high-profile U.S. health care investments, including Medtronic, Charles River Laboratories, DexCom, and Catalent. The activist firm also holds a stake in German health care firm Sartorius, of which BIO owns 38% of outstanding common shares. We recently downgraded our view on BIO to Sell from Hold. The company reduced revenue and margin expectations during Q1 2026 earnings due to headwinds from the ongoing U.S.-Iran conflict, including weaker diagnostics sales and higher freight costs. We think the near-term operating environment for BIO and peers remains highly challenging, with ongoing weakness in key end markets such as academia and smaller biotech continuing to pressure performance.

$BIO

Research43d ago

Research Alert: Bio-rad Laboratories Rallies On Wsj Report Of Elliott Management Stake

$BIO

Research43d ago

Research Alert: CFRA Maintains Hold Opinion On Shares Of Adss Of Iqiyi Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target price to USD1.20 from USD1.30 based on 13.9x Forward P/E. This is in turn based on a five-year average valuation for the stock. We believe that an average valuation is justified as iQIYI is in a transitional phase with both opportunities and challenges. iQIYI reported Q1 2026 revenues of CNY 6.23B, down 13% YoY, with declines across all segments: membership services (-5%), online advertising (-7%), content distribution (-43%), and others (-49%). The company swung to an operating loss of CNY 228.4M from CNY 341.9M profit YoY, and net loss of CNY 294.6M versus CNY 182.1M profit. We cut 2026 EPS to CNY0.59 from CNY0.65 and 2027 EPS to CNY0.89 from CNY0.99. The stock remains a Hold due to near-term headwinds including revenue declines and profitability pressures, balanced by management's AI cost initiatives, overseas growth momentum, and market leadership position. The Hong Kong listing and share buyback program signal confidence.

$IQ

Research43d ago

Research Alert: Fbin Q1: Eps Falls 20%; Company Cuts Full-year Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:FBIN reported Q1 2026 sales declining 2.1% to $1.01B, with GAAP EPS falling 51.8% to $0.20, impacted by $42.4M in governance advisory and leadership transition costs. EPS before charges declined 19.7% to $0.53 as operating margin before charges contracted 200 bps to 11.1%, with Water Innovations margin down 120 bps and Outdoors margin declining 300 bps. The company revised 2026 guidance lower, expecting sales down low-single digits versus prior flat to up 2% guidance, while EPS before charges guidance was cut to $3.00-$3.30 from $3.35-$3.65. Management cited increased commodity inflation and weakened consumer sentiment as factors driving the revision. The company maintains a solid balance sheet with $223M cash, over $900M liquidity, and 2.9x net debt/EBITDA, while continuing capital returns with $43.5M in share repurchases and $31.2M in dividends during the quarter, though interim leadership remains in place for both CEO and CFO roles.

$FBIN

Research43d ago

Citi Upgrades Saab to Neutral Rating, Lifts PT

Citi on Monday upgraded Swedish defense and security group Saab (SAAB-B.ST) to neutral from sell and increased its price target to 527.00 kronor from 516.00 kronor.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SAAB-B.ST

Research43d ago

AlphaValue/Baader Europe Downgrades Holcim to Add, Lowers PT

AlphaValue/Baader Europe on Monday downgraded building materials company Holcim (HOLN.SW) to add from buy and reduced its price target to 93.20 francs from 96.40 francs.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$HOLN.SW

Showing 2281-2300 of 6317